November 4-5, 2013 | Boston Marriott Cambridge | Cambridge, MA
The promise of personalized medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development is also a driving force in the use of biomarkers. Cambridge Healthtech Institute’s Fifth Annual Clinical and Translational Biomarkers meeting will cover the timeline in developing companion diagnostics, clinical and analytical biomarker validation, and the role of biomarkers in clinical decision making.
Biomarkers to predict response to therapy
Biomarker utility in clinical trials
Biomarkers for safety assessment
Incorporating companion diagnostic strategy into drug development
Implementing personalized medicine
Consortia and collaboration in biomarker development
Scientists who wish to present their knowledge and expertise to their colleagues are asked to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.
If you are interested in presenting, please click here to submit your proposal.
Deadline for submission is Friday, May 3, 2013
For more information, please contact:Julia Boguslavsky
Executive Director, Conferences
For sponsorship information, please contact:Ilana Quigley
Manager, Business Development